Please use this identifier to cite or link to this item:
Title: Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial.
Austin Authors: Herbst, Roy S;Wu, Yi-Long;John, Thomas ;Grohe, Christian;Majem, Margarita;Wang, Jie;Kato, Terufumi;Goldman, Jonathan W;Laktionov, Konstantin;Kim, Sang-We;Yu, Chong-Jen;Vu, Huu Vinh;Lu, Shun;Lee, Kye Young;Mukhametshina, Guzel;Akewanlop, Charuwan;de Marinis, Filippo;Bonanno, Laura;Domine, Manuel;Shepherd, Frances A;Urban, Damien;Huang, Xiangning;Bolanos, Ana;Stachowiak, Marta;Tsuboi, Masahiro
Affiliation: Medical Oncology, Yale School of Medicine and Yale Cancer Center, New Haven, CT.
Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China.
Medical Oncology
Klinik für Pneumologie-Evangelische Lungenklinik Berlin Buch, Berlin, Germany.
Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China.
Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan.
David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA.
Federal State Budgetary Institution "N.N.Blokhin National Medical Research Center of Oncology" of the Ministry of Health of the Russian Federation, Moscow, Russia.
Department of Oncology, Asan Medical Center, Seoul, South Korea.
Department of Internal Medicine, National Taiwan University College of Medicine, Taipei, Taiwan.
Department Thoracic Surgery, Cho Ray Hospital, Hochiminh City, Vietnam.
Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
Precision Medicine Lung Cancer Center, Konkuk University Medical Center, Seoul, South Korea.
Republican Clinical Oncology Center, Kazan, Republic of Tatarstan, Russia.
Division of Medical Oncology, Faculty of Medicine, Siriraj Hospital, Bangkok, Thailand.
Thoracic Oncology Division, European Institute of Oncology (IEO), IRCCS, Milan, Italy.
Medical Oncology 2, Istituto Oncologico Veneto IOV IRCCS, Padova, Italy.
Department of Oncology, Hospital Universitario Fundación Jiménez Díaz (IIS-FJD), Madrid, Spain.
Department of Medical Oncology and Hematology, University Health Network, Princess Margaret Cancer Center, Toronto, Canada.
Department of Oncology, Sheba Medical Center, Tel Hashomer, Israel.
Oncology Biometrics, AstraZeneca, Cambridge, United Kingdom.
Oncology Research and Development, AstraZeneca, Toronto, Ontario, Canada.
Late Oncology Research and Development, AstraZeneca, Warsaw, Poland.
Department of Thoracic Surgery and Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Issue Date: 31-Jan-2023 2023
Publication information: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2023
Abstract: The phase III ADAURA ( identifier: NCT02511106) primary analysis demonstrated a clinically significant disease-free survival (DFS) benefit with adjuvant osimertinib versus placebo in EGFR-mutated stage IB-IIIA non-small-cell lung cancer (NSCLC) after complete tumor resection (DFS hazard ratio [HR], 0.20 [99.12% CI, 0.14 to 0.30]; P < .001). We report an updated exploratory analysis of final DFS data.
DOI: 10.1200/JCO.22.02186
ORCID: 0000-0003-2535-5847
Journal: Journal of Clinical oncology: Official Journal of the American Society of Clinical Oncology
Start page: JCO2202186
PubMed URL: 36720083
ISSN: 1527-7755
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Mar 30, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.